TPN672 displayed robust antipsychotic efficacy, significantly higher than aripiprazole in rodent models (such as blocked phencyclidine-induced hyperactivity , and ameliorated negative symptoms and cognitive deficits in sociability test, dark avoidance response, Morris water maze test, and novel object recognition test).
Moreover, the safety margin (the ratio of minimum catalepsy inducing dose to minimum effective dose) of TPN672 was about 10-fold, superior to aripiprazole. In conclusion, TPN672 is a promising new drug candidate for the treatment of schizophrenia, and has been shown to be more effective in attenuating negative symptoms and cognitive deficits, meanwhile have lower risk of EPS (Extrapyramidal symptoms) and hyperprolactinemia.